336 related articles for article (PubMed ID: 29581297)
1. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
2. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.
Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y
J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848
[TBL] [Abstract][Full Text] [Related]
3. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
4. Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands.
Zhong J; Yang X; Chen J; He K; Gao X; Wu X; Zhang M; Zhou H; Xiao F; An L; Wang X; Shi Y; Zhang N
Nat Commun; 2022 Aug; 13(1):4795. PubMed ID: 35970825
[TBL] [Abstract][Full Text] [Related]
5. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
8. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Bugide S; Gupta R; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301901
[TBL] [Abstract][Full Text] [Related]
12. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
13. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.
Yin J; Leavenworth JW; Li Y; Luo Q; Xie H; Liu X; Huang S; Yan H; Fu Z; Zhang LY; Zhang L; Hao J; Wu X; Deng X; Roberts CW; Orkin SH; Cantor H; Wang X
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15988-93. PubMed ID: 26668377
[TBL] [Abstract][Full Text] [Related]
14. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma.
Abdelrahman MM; Fawzy IO; Bassiouni AA; Gomaa AI; Esmat G; Waked I; Abdelaziz AI
Hum Immunol; 2016 Aug; 77(8):667-673. PubMed ID: 27262453
[TBL] [Abstract][Full Text] [Related]
15. Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression.
Zhang Y; Tang B; Song J; Yu S; Li Y; Su H; He S
J Exp Clin Cancer Res; 2019 Feb; 38(1):92. PubMed ID: 30786928
[TBL] [Abstract][Full Text] [Related]
16. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
17. Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression.
Sun X; Sui Q; Zhang C; Tian Z; Zhang J
Mol Cancer Ther; 2013 Dec; 12(12):2885-96. PubMed ID: 24107450
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of CTCF reduces the binding of EZH2 and affects the methylation of the SOCS3 promoter in hepatocellular carcinoma.
Wei L; Liu Q; Huang Y; Liu Z; Zhao R; Li B; Zhang J; Sun C; Gao B; Ding X; Yu X; He J; Sun A; Qin Y
Int J Biochem Cell Biol; 2020 Mar; 120():105685. PubMed ID: 31917284
[TBL] [Abstract][Full Text] [Related]
19. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
20. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
